Virobay, an early-stage biotech with a drug platform for pain and autoimmune diseases, withdrew its plans for an initial public offering on Friday. The company originally planned to raise $50 million during the week of October 13.
Virobay's drug development platform is based on inhibiting cysteine cathepsins enzymes that are active in the biology of many diseases.
Help employers find you! Check out all the jobs and post your resume.
Virobay's drug development platform is based on inhibiting cysteine cathepsins enzymes that are active in the biology of many diseases.
Help employers find you! Check out all the jobs and post your resume.
